Use of interleukin-22 in treating viral hepatitis
AssigneeGeneron (Shanghai) Corporation Ltd.
InventorsXiaoqiang Yan, Zhihua Huang, Hongzhou Yang, Yuliang Huang
Life of this patent
Estimating the term…
Abstract
This invention relates to a use of IL-22 in the treatment of viral hepatitis. As illustrated in the examples of this invention, IL-22 can significantly reduce liver damage caused by hepatitis virus, and can significantly reduce the increase of transaminase ALT/AST induced by hepatitis virus. In addition, the IL-22 dimer of this invention can effectively treat viral hepatitis.
Claims8
A polypeptide comprising interleukin 22 (IL-22) and an Fc-fragment of human IgG2, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2.
A polypeptide comprising interleukin 22 (IL-22) and an Fc-fragment of human IgG2, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:3.
A polypeptide comprising interleukin 22 (IL-22) and an Fc-fragment of human IgG2, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:4.
An interleukin 22 (IL-22) dimer comprising two IL-22 monomers of a polypeptide comprising IL-22 and an Fc fragment of human IgG2, wherein the Fc fragment comprises amino acid residues 163-385 of SEQ ID NO:2.
Dependencies are inferred from the claim text.